Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

Cosmologists are increasingly entertaining a radical possibility: that the cosmos might fold back on itself so that, on the ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

A secretive scientist, Dr “Hap” Percy, studies people with near-death histories to test if consciousness can cross dimensions ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

The roots of Russia's invasion of Ukraine go back decades and run deep. The current conflict is more than one country fighting to take over another; it is — in the words of one U.S. official — a shift ...